Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Earnings for Altamira Therapeutics Ltd. (CYTO)
Earnings in 2023 (TTM): $-7,270,038
According to Altamira Therapeutics Ltd.'s latest financial reports the company's current earnings (TTM) are $-7,270,038. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Altamira Therapeutics Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-7,270,038 | $-7,270,038 |
| 2022 | $-26,538,740 | $-26,528,411 |
| 2021 | $-17,368,546 | $-17,390,166 |
| 2020 | $-8,221,449 | $-8,200,165 |
| 2019 | $-6,825,738 | $-6,631,901 |
| 2018 | $-11,334,224 | $-11,496,401 |
| 2017 | $-24,427,247 | $-24,409,474 |
| 2016 | $-30,793,306 | $-30,662,251 |
| 2015 | $-29,705,000 | $-29,705,000 |
| 2014 | $-18,185,000 | $-18,185,000 |
| 2013 | $-14,698,743 | $-15,004,493 |
| 2012 | $-4,602,409 | $-4,602,409 |